HIV gp160 vaccine - Hyland Immuno

Drug Profile

HIV gp160 vaccine - Hyland Immuno

Latest Information Update: 08 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hyland Immuno
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 10 Sep 1999 New profile, split from generic HIV gp160 profile
  • 28 Nov 1994 Phase-I clinical trials for HIV-1 infections in USA (Injection)
  • 28 Nov 1994 Phase-II clinical trials for HIV-1 infections in Austria (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top